Recent large clinical trials have demonstrated that HMG-CoA reductase inhibitors, or statins,
markedly reduce morbidity and mortality when used in the primary and secondary …

Clinical trials of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor
(statin) therapy have demonstrated improvement in coronary atherosclerosis progression …

The 3-hydroxy-3-methylglutaryl (HMG)-coenzyme A (CoA) reductase inhibitors (statins) have
been shown to exhibit several vascular protective effects, including antithrombotic …

The study was aimed to investigate the effect of two different statins on the levels of
haemostatic variables reflecting procoagulant and fibrinolytic activity in patients with …

The results of several clinical studies investigating the effect of statin therapy on the
fibrinolytic system in vivo are inconclusive. We compared the effect of six different statins …

Statins have a variable response on fibrinogen, and these changes may have implications
on cardiovascular events. In this randomized placebo-controlled crossover study, we …

There is evidence indicating that statins (3-hydroxy-methylglutaryl coenzyme A reductase
inhibitors) may produce several cholesterol-independent antithrombotic effects. In this …

Summary Background: Statins [3-hydroxymethyl-3-methylglutaryl coenzyme A (HMG-CoA)
reductase inhibitors] and antiplatelet therapy reduce the risk of atherosclerotic disease …

Clinical trials of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors or
statin therapy have demonstrated that baseline or treated low-density lipoprotein (LDL) …

The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors or statins are potent
inhibitors of cholesterol biosynthesis. Several large clinical trials have demonstrated the …